Stock Scorer

OSE IMMUNOTHERAPEUTICS (OSE.PA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in EUR. Every figure as a table ›

Revenue Annual

0 25M 50M 75M FY20: 10.4M FY21: 26.3M FY23: 2.2M FY24: 69.9M FY25: 2.6M FY20 FY21 FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY20: -19M FY21: -16.6M FY23: -23M FY24: 43.7M FY25: -37.5M FY20 FY21 FY23 FY24 FY25

Net Income Annual

-45M -30M -15M 0 15M 30M 45M FY20: -16.6M FY21: -16.9M FY23: -23M FY24: 37.4M FY25: -37.7M FY20 FY21 FY23 FY24 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-40M -20M 0 20M 40M 60M FY20: -19.6M FY21: -9.9M FY23: -19.8M FY24: 48.4M FY25: -34M FY20 FY21 FY23 FY24 FY25

Free Cash Flow Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.